Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05163886 · ClinicalTrials.gov registry record · Phase 2
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
A Phase 2 study, sponsored by OrphAI Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT05163886 is a Phase 2 study that has completed, run by OrphAI Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT05163886, a Phase 2 study, has completed, sponsored by OrphAI Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).
Interventions
- OTHER Placebo
- DRUG LAM-002A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-12-23 |
| Est. Completion | 2025-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05163886
The ClinicalTrials.gov registry entry for NCT05163886 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OrphAI Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05163886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05163886 about?
NCT05163886 is a clinical study titled "Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis". This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).
What is the current status of trial NCT05163886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2021-12-23. Estimated completion is 2025-05-31.
What interventions are being tested in trial NCT05163886?
The interventions under investigation include: Placebo (OTHER), LAM-002A (DRUG).
Who is sponsoring clinical trial NCT05163886?
This trial is sponsored by OrphAI Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.